A Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (GU17-295)
A Trial of Atezolizumab Plus Chemotherapy After Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma (GU17-295)
Trial Category:
Genitourinary
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
